{
    "organizations": [],
    "uuid": "a6459372b0f997e0267c8a5569dc95d5857403df",
    "author": "",
    "url": "https://www.reuters.com/article/brief-lilly-announces-cyramza-phase-3-re/brief-lilly-announces-cyramza-phase-3-reach-2-study-met-overall-survival-endpoint-idUSFWN1RH04E",
    "ord_in_thread": 0,
    "title": "BRIEF-Lilly Announces CYRAMZA Phase 3 REACH-2 Study Met Overall Survival Endpoint",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "  Updated 12 minutes ago BRIEF-Lilly Announces CYRAMZA Phase 3 REACH-2 Study Met Overall Survival Endpoint Reuters Staff 2 Min Read \nApril 4 (Reuters) - Eli Lilly and Co: \n* LILLY ANNOUNCES CYRAMZA® (RAMUCIRUMAB) PHASE 3 REACH-2 STUDY IN SECOND-LINE HEPATOCELLULAR CARCINOMA PATIENTS MET OVERALL SURVIVAL ENDPOINT \n* TRIAL ‍MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS) AS WELL AS SECONDARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS)​ \n* ‍CYRAMZA HAS NOW DEMONSTRATED A SURVIVAL BENEFIT IN FOUR AGGRESSIVE, DIFFICULT-TO-TREAT TUMOR TYPES IN PHASE 3 STUDIES​TREAT TUMOR TYPES IN PHASE 3 STUDIES​ \n* LILLY INTENDS TO INITIATE REGULATORY SUBMISSIONS IN MID-2018 \n* SAFETY PROFILE OBSERVED IN REACH-2 STUDY WAS CONSISTENT WITH WHAT HAS BEEN PREVIOUSLY OBSERVED FOR SINGLE-AGENT CYRAMZA \n* ONLY GRADE ≥3 ADVERSE EVENTS OCCURRING AT A RATE OF 5 PERCENT OR GREATER IN CYRAMZA ARM WERE HYPERTENSION AND HYPONATREMIA \n* AN ONGOING PHASE 3 TRIAL IN ADVANCED UROTHELIAL CARCINOMA HAS MET ITS PRIMARY ENDPOINT OF PFS, AND OS DATA EXPECTED IN H1 2018 \n* ‍ANOTHER ONGOING PHASE 3 STUDY OF CYRAMZA IN EGFR-POSITIVE NON-SMALL CELL LUNG CANCER IS ONGOING, WITH EXPECTED PFS DATA READOUT IN LATE 2018​​  ",
    "published": "2018-04-04T13:58:00.000+03:00",
    "crawled": "2018-04-04T14:16:52.034+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "announces",
        "cyramza",
        "phase",
        "study",
        "met",
        "overall",
        "survival",
        "endpoint",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "eli",
        "lilly",
        "co",
        "lilly",
        "announces",
        "ramucirumab",
        "phase",
        "study",
        "hepatocellular",
        "carcinoma",
        "patient",
        "met",
        "overall",
        "survival",
        "endpoint",
        "trial",
        "primary",
        "endpoint",
        "overall",
        "survival",
        "o",
        "well",
        "secondary",
        "endpoint",
        "survival",
        "pfs",
        "demonstrated",
        "survival",
        "benefit",
        "four",
        "aggressive",
        "tumor",
        "type",
        "phase",
        "tumor",
        "type",
        "phase",
        "lilly",
        "intends",
        "initiate",
        "regulatory",
        "submission",
        "safety",
        "profile",
        "observed",
        "study",
        "consistent",
        "previously",
        "observed",
        "cyramza",
        "grade",
        "adverse",
        "event",
        "occurring",
        "rate",
        "percent",
        "greater",
        "cyramza",
        "arm",
        "hypertension",
        "hyponatremia",
        "ongoing",
        "phase",
        "trial",
        "advanced",
        "urothelial",
        "carcinoma",
        "met",
        "primary",
        "endpoint",
        "pfs",
        "o",
        "data",
        "expected",
        "h1",
        "ongoing",
        "phase",
        "study",
        "cyramza",
        "cell",
        "lung",
        "cancer",
        "ongoing",
        "expected",
        "pfs",
        "data",
        "readout",
        "late"
    ]
}